Peptides Similar to Sermorelin

Peptides Related to Sermorelin#

Sermorelin belongs to the broader category of growth hormone secretagogues (GHS) -- compounds that stimulate the pituitary gland to release growth hormone. Within this category, there are two primary mechanistic classes: GHRH receptor agonists (like sermorelin and tesamorelin) and ghrelin receptor agonists (like ipamorelin, GHRP-2, GHRP-6, and hexarelin). Understanding the distinctions between these classes is essential for evaluating their relative merits in research and clinical applications.

GHRH Receptor Agonists#

Sermorelin vs. Tesamorelin#

Tesamorelin (Egrifta) is the most direct structural relative of sermorelin, consisting of GHRH(1-44) with a trans-3-hexenoic acid modification at the N-terminus. This modification protects against DPP-IV cleavage, substantially extending its biological half-life compared to sermorelin.

Key differences:

• Regulatory status: Tesamorelin is currently FDA-approved for treatment of HIV-associated lipodystrophy; sermorelin's FDA approval was withdrawn in 2008 due to manufacturing issues
• Sequence length: Tesamorelin uses the full 44-amino acid GHRH sequence vs. sermorelin's 29-residue truncation
• Pharmacokinetics: Tesamorelin has a longer duration of action due to DPP-IV resistance
• Clinical evidence: Tesamorelin has been studied in large randomized controlled trials demonstrating visceral fat reduction in HIV-associated lipodystrophy

Sermorelin vs. CJC-1295#

CJC-1295 represents a further evolution of the GHRH analog concept. Modified GRF(1-29) (also called CJC-1295 without DAC or Mod-GRF) contains four amino acid substitutions that enhance metabolic stability. The DAC (Drug Affinity Complex) variant binds to serum albumin, extending its half-life to approximately 8 days.

• CJC-1295 without DAC: Similar to sermorelin but with enhanced protease resistance; half-life of approximately 30 minutes
• CJC-1295 with DAC: Dramatically extended half-life (6-8 days) enabling weekly dosing, but sustained GH elevation may disrupt normal pulsatility

Ghrelin Receptor Agonists (GHRPs)#

Sermorelin vs. Ipamorelin#

Ipamorelin is a pentapeptide GHRP that acts through the growth hormone secretagogue receptor (GHS-R1a), the same receptor activated by the endogenous hormone ghrelin. It is considered the most selective GHRP in its class.

Comparative features:

The combination of sermorelin and ipamorelin is among the most commonly studied GH secretagogue protocols, leveraging complementary pathways to produce a GH response greater than either agent alone.

Sermorelin vs. GHRP-2#

GHRP-2 is a synthetic hexapeptide that activates GHS-R1a with high potency. Unlike ipamorelin, GHRP-2 also stimulates cortisol and prolactin release at higher doses, indicating less selectivity for the GH axis.

• GHRP-2 produces a more robust acute GH release than ipamorelin at equivalent doses
• Appetite stimulation is more pronounced with GHRP-2 due to ghrelin-like activity
• GHRP-2 shows less tachyphylaxis than hexarelin during chronic administration
• The sermorelin + GHRP-2 combination has been studied in clinical research demonstrating synergistic GH release

Sermorelin vs. Hexarelin#

Hexarelin is the most potent synthetic GHRP but is limited by significant tachyphylaxis (desensitization) with chronic use. It also has GH-independent effects on the cardiovascular system, including cardioprotective actions mediated through the CD36 receptor.

• Hexarelin produces the highest peak GH levels among GHRPs in single-dose studies
• Chronic hexarelin administration leads to progressive reduction in GH response over weeks
• Hexarelin significantly raises both cortisol and prolactin, limiting its selectivity
• The cardiovascular effects of hexarelin are unique among GHRPs and are being investigated independently of GH release

Combination Approaches#

Research has increasingly focused on multi-peptide approaches that combine GHRH and GHRP pathways. The rationale is based on demonstrated synergism:

1. GHRH + GHRP synergy: GHRH agonists (sermorelin) and GHRP agonists (ipamorelin) activate distinct intracellular signaling cascades. GHRH activates the cAMP/PKA pathway, while GHRPs activate phospholipase C and protein kinase C pathways. The convergence of these signals at the level of calcium mobilization produces amplified GH secretion.

2. Somatostatin suppression: GHRPs reduce hypothalamic somatostatin release, removing tonic inhibition of GH secretion. When combined with a GHRH agonist, the removal of somatostatin inhibition allows the GHRH signal to produce a maximal GH response.

3. Sustained pituitary support: Sermorelin's unique ability to increase pituitary GH mRNA provides a sustained increase in GH synthetic capacity that complements the acute release effects of GHRPs.

Evidence Gaps#

Direct head-to-head comparison studies between sermorelin and related peptides are limited. Most comparisons rely on separate studies conducted in different populations with varying methodologies. Rigorous randomized trials comparing sermorelin to tesamorelin, ipamorelin, and combination protocols in standardized aging populations would significantly advance the field.

Related Reading#

• Sermorelin overview and research guide
• Sermorelin research evidence
• Sermorelin dosing protocols